Want to see AU:SNT full AI Analyst Report?
Top Page
Syntara Limited
(Sydney:SNT)
Select Model
Select Model
Rating:46Neutral
Price Target:
AU$0.03
â–Ľ(-16.67% Downside)
Action:N/A
Date:08/29/26
The score is held down primarily by weak financial performance—continued losses, no meaningful recent revenue, and negative operating/free cash flow—despite a low-debt balance sheet. Technical indicators add only modest support with mixed trend signals, while valuation remains challenged due to negative earnings and no dividend.
Positive Factors
Very Low Leverage
The absence of meaningful debt limits interest obligations and refinancing risk. This gives Syntara greater financial flexibility than in earlier periods of higher leverage, although the benefit is constrained by ongoing losses and negative cash generation.
Negative Factors
No Recent Revenue
The absence of recent reported revenue leaves the business without demonstrated commercial scale and makes future results dependent on restarting or establishing sales. This materially weakens revenue visibility and limits confidence in sustainable operations.
Read all positive and negative factors
Positive Factors
Negative Factors
Very Low Leverage
The absence of meaningful debt limits interest obligations and refinancing risk. This gives Syntara greater financial flexibility than in earlier periods of higher leverage, although the benefit is constrained by ongoing losses and negative cash generation.
Read all positive factors
Syntara Limited (SNT) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$51.04M
Dividend YieldN/A
Average Volume (3M)3.71M
Price to Earnings (P/E)―
Beta (1Y)2.94
Revenue GrowthN/A
EPS Growth-8.00%
CountryAU
Employees85
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,963,019,300
10 Day Avg. Volume2,483,870
30 Day Avg. Volume3,709,067
Financial Highlights & Ratios
PEG Ratio-1.96
Price to Book (P/B)2.06
Price to Sales (P/S)0.00
P/FCF Ratio-3.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.11Price Target Upside250.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Syntara Limited Business Overview & Revenue Model
Company Description
Syntara Limited is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies by targeting extracellular matrix dysfunction, primarily through amine oxidase chemistry. Headquartered in Frenchs Forest, Australia, the co...
Syntara Limited Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 5.76M | 5.76M | 7.43M |
| Gross Profit | -146.00K | 0.00 | 3.06M | 3.06M | 7.43M |
| EBITDA | -16.21M | -12.00M | -9.29M | -12.15M | 551.00K |
| Net Income | -9.00M | -7.92M | -11.36M | -1.94M | -2.97M |
Balance Sheet | |||||
| Total Assets | 19.14M | 21.44M | 24.03M | 25.19M | 33.59M |
| Cash, Cash Equivalents and Short-Term Investments | 13.56M | 15.08M | 9.23M | 8.94M | 18.71M |
| Total Debt | 0.00 | 84.00K | 2.04M | 4.29M | 6.32M |
| Total Liabilities | 2.92M | 5.42M | 14.47M | 14.38M | 30.75M |
| Stockholders Equity | 16.21M | 16.02M | 9.56M | 10.80M | 2.85M |
Cash Flow | |||||
| Free Cash Flow | -9.78M | -11.12M | -7.42M | -16.61M | 2.42M |
| Operating Cash Flow | -9.78M | -11.12M | -7.28M | -16.30M | 3.07M |
| Investing Cash Flow | -2.00K | 4.18M | -131.00K | -306.00K | -644.00K |
| Financing Cash Flow | 8.26M | 18.46M | 6.98M | 6.63M | 1.52M |
Syntara Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | AU$56.30M | -13.70 | -1.67% | ― | 15.21% | -141.82% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$16.57M | -3.73 | 1.66% | 6.67% | 5.74% | -222.22% | |
50 Neutral | AU$2.90M | -0.33 | -76.30% | ― | 3.64% | -23.56% | |
48 Neutral | AU$6.64M | 0.24 | 93.89% | ― | -24.22% | ― | |
46 Neutral | AU$51.04M | -4.81 | -61.92% | ― | ― | -8.00% | |
39 Underperform | AU$20.02M | -5.07 | 4388.00% | ― | -19.29% | 62.42% |
* Healthcare Sector Average
AU:SNT
Syntara Limited
0.03
0.00
0.00%
AU:EXL
Elixinol Wellness
0.02
>-0.01
-11.76%
AU:CAN
Cann Group
0.01
>-0.01
-23.08%
AU:LGP
Little Green Pharma Ltd.
0.07
-0.06
-49.23%
AU:PKP
Althea Group Holdings Ltd.
0.01
>-0.01
-33.33%
AU:VIT
Cronos Australia Ltd.
0.03
-0.04
-62.69%
Syntara Limited Corporate Events
Syntara Loss Widens as Revenue Falls and Asset Base Shrinks
Aug 27, 2026
For the 2026 financial year, Syntara reported a 7.9% decline in revenues and other income to $7.0 million and a 13.6% increase in net loss to $9.0 million, with no dividends paid or declared for either the current or prior year. Net tangible asset...
Syntara to Brief Investors on Expanding Clinical Pipeline in Quarterly Webinar
Jul 27, 2026
Syntara Limited will host an investor webinar on 28 July 2026 to provide an update on recent announcements and its latest quarterly cash flow report, with CEO Gary Phillips presenting the company’s progress and outlook. The session, which of...
Syntara secures FDA backing and funding as key clinical programs advance
Jul 26, 2026
Syntara Limited reported a pivotal June quarter, marked by positive U.S. FDA feedback endorsing the design of a ~100-patient Phase 2b trial of lead candidate amsulostat in myelofibrosis, reinforcing its path toward late-stage development and bolst...
Syntara Releases Early Phase 2a Data on SNT-4728 for Sleep Disorder
Jul 6, 2026
Syntara Limited has released preliminary information on a phase 2a trial of its drug candidate SNT-4728 for idiopathic REM sleep behavior disorder, with CEO Gary Phillips presenting the early data in a dedicated webinar on 6 July 2026. The update ...
Syntara reports early Phase 2 evidence of brain inflammation reduction in prodromal Parkinson’s trial
Jul 5, 2026
Syntara Limited has reported preliminary data from a randomised, double-blind, placebo-controlled Phase 2 trial of its oral anti-inflammatory candidate SNT-4728 in 41 patients with isolated REM Sleep Behaviour Disorder, a precursor to Parkinson...
Syntara Shares Halted Ahead of Key Parkinson’s Trial Update
Jul 2, 2026
Syntara Limited has requested and been granted a trading halt in its ordinary shares on the ASX, effective from 3 July 2026, while it prepares an announcement on preliminary results from its iRBD Parkinson’s disease study of lead candidate S...
Syntara Issues 1.75 Million Unquoted Performance Rights Under Incentive Scheme
Jul 2, 2026
Syntara Limited has issued 1,754,015 unquoted performance rights under its employee incentive scheme, with the securities recorded under the ASX code SNTAAS. These rights are subject to transfer restrictions and will remain unquoted on the ASX unt...
Syntara Limited Seeks ASX Quotation for Additional Shares
Jul 2, 2026
Syntara Limited has applied for ASX quotation of 1,113,000 new ordinary fully paid shares under code SNT, with an issue date of July 2, 2026. The move modestly expands the company’s listed capital base, potentially enhancing liquidity for ex...
Syntara Shifts CEO Pay Toward Long-Term Equity Incentives
Jul 2, 2026
Syntara Limited’s board has resolved to grant unlisted zero exercise price options as performance rights to its Chief Executive Officer in lieu of a portion of his FY27 cash salary, subject to shareholder approval at the 2026 annual general ...
Syntara advances scar therapy trials as Phase 1b recruitment passes halfway mark
Jul 1, 2026
Syntara Limited reported that recruitment for its Phase 1b trial of topical pan-lysyl oxidase inhibitor SNT-9465 in hypertrophic sternotomy scars has surpassed 50%, with 60% of participants now on treatment and enrolment expected to complete in th...
Syntara Completes Second Tranche of A$8m Share Placement
Jun 24, 2026
Syntara Limited has completed the second tranche of its previously announced capital raising, issuing 53,690,885 new fully paid ordinary shares at A$0.027 each to secure part of the planned A$8 million placement, alongside an intended A$2 million ...
Syntara Seeks ASX Quotation for 53.7 Million New Shares
Jun 24, 2026
Syntara Limited has applied to the Australian Securities Exchange for quotation of 53,690,885 ordinary fully paid shares, expanding the number of its listed securities under the ticker SNT. The new securities, issued on June 25, 2026, form part of...
Syntara Wins Shareholder Backing for Capital Resolutions to Fund Drug Pipeline
Jun 23, 2026
Syntara Limited, listed on the ASX under the code SNT, is a clinical-stage biotechnology developer of novel treatments for blood cancers, fibrotic and inflammatory diseases, and neurodegenerative conditions, with a portfolio led by amsulostat for ...
Syntara Secures A$8.84m to Extend Runway and Advance Drug Pipeline
Jun 10, 2026
Syntara Limited has completed a Share Purchase Plan that raised approximately A$0.84 million from eligible shareholders at a discounted issue price of A$0.027 per share, resulting in the issuance of over 31 million new shares. Combined with a prio...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.